Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-29T02:54:22.702Z Has data issue: false hasContentIssue false
  • English
  • Français

Reply to Tan et al

Published online by Cambridge University Press:  10 May 2016

David T. Kuhar ,
Kimberly A. Struble  and
David K. Henderson
David T. Kuhar*
Affiliation:
Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
Kimberly A. Struble
Affiliation:
Division of Antiviral Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland
David K. Henderson
Affiliation:
Office of the Deputy Director for Clinical Care, Clinical Center, National Institutes of Health, Bethesda, Maryland
*
Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, MS A-31, Atlanta, GA 30333 ([email protected])
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letters to the Editor
Information
Infection Control & Hospital Epidemiology , Volume 35 , Issue 3 , March 2014 , pp. 328 - 329
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2014

References

1. Tan, DHS, Goddey-Erikefe, B, Yoong, D, et al. Selecting an antiretroviral regimen for human immunodeficiency virus postexposure prophylaxis in the occupational setting. Infect Control Hosp Epidemiol 2013;35:326–328.CrossRefGoogle Scholar
2. Kuhar, DT, Henderson, DK, Struble, KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol 2013;34:875–892.Google Scholar
3. Mayer, KH, Mimiaga, MJ, Gelman, M, Grasso, C. Raltegravir, te-nofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr 2012;59:354–359.Google Scholar
4. McAllister, J, Read R McNulty, A, Tong, W, Ingersoll, A, Carr, A. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. HIV Med 2014;15:13–22.Google Scholar
5. Tosini, W, Muller, P, Prazuck, T, et al. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinivir/ ritonavir tablet formation. AIDS 2010;24:2375–2380 CrossRefGoogle Scholar
6. Henderson, DK. Human immunodeficiency virus in healthcare settings. In: Mandeli, GL, Bennett, JE, Dolin, R, eds. Principles and Practice of Infectious Diseases. 7th ed. New York: Churchill Livingstone, 2009;3753–3770.Google Scholar
7. New York State Department of Health AIDS Institute. HIV Prophylaxis Following Occupational Exposure. New York: New York State Department of Health AIDS Institute, 2012. http://www.hivguidelines.org/clinical-guidelines/post-exposure-prophylaxis/hiv-prophylaxis-following-occupational-exposure/. Accessed November 26, 2013.Google Scholar